A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer

Simple item page
dc.contributor.authorDarendeliler, Emin
dc.contributor.authorKizir, Ahmet
dc.contributor.authorTuncel, Nina
dc.contributor.authorOral, Ethem Nezih
dc.contributor.authorKaradeniz, Ahmet
dc.contributor.authorBilge, Nijad
dc.contributor.buuauthorSarıhan, Süreyya
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.tr_TR
dc.contributor.scopusid19837255600tr_TR
dc.date.accessioned2021-10-22T22:56:00Z
dc.date.available2021-10-22T22:56:00Z
dc.date.issued1998
dc.description.abstractPurpose: A prospective phase II trial was conducted by the Institute of Oncology, istanbul University in December 1994 on patients with locally-advanced non-small cell lung cancer to assess acute toxicity and the feasibility of a combination of radiosensitizer and accelerated radiotherapy with concomitant boost. Materials and methods: Patients were irradiated using 'large' fields (primary tumour and locoregional lymph nodes) with 1.8 Gy per fraction, five fractions a week. Reduced 'boost' fields (primary and involved nodes only) were also irradiated twice-weekly 1.8 Gy per fraction in ten fractions concomitantly 6 h after the administration of large field. Total radiation dose was 63 Gy in 5 weeks (45 Gy 'large' fields and 18 Gy 'boost'). The maximum allowed dose to the spinal cord was 3750 cGy. Cisplatinum, 6 mg/m(2) was given daily just before 'large' field irradiation, Results: As of January1997, 15 patients were evaluated (median follow-up of 12.5 months with a range of 5.5-23 months). The overall acute toxicity rate was 38% and Grade 3 acute toxicity was 8%. Grade 4 or greater acute toxicities were not observed. The overall rate of cisplatinum-induced nausea and vomiting was 80% (severe in 60%), but all were easily treated with antiemetics. Complete response rate (clinical and radiological) was 40% and an overall response rate was 73%. Median survival was 16 months and progression-free survival was 5.5 months (range of 2.5-21 months). Conclusions: Toxicity was well tolerated and no treatment-related death occurred with this combined treatment regimen. Although it appears that better local control rates can be achieved, additional phase II/III studies are needed.en_US
dc.identifier.citationSarıhan, S. vd. (1998). "A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer". Lung Cancer, 20(1), 37-46.en_US
dc.identifier.endpage46tr_TR
dc.identifier.issn0169-5002
dc.identifier.issue1tr_TR
dc.identifier.pubmed9699186tr_TR
dc.identifier.scopus2-s2.0-0031718511tr_TR
dc.identifier.startpage37tr_TR
dc.identifier.urihttps://doi.org/10.1016/S0169-5002(98)00003-8
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0169500298000038
dc.identifier.urihttp://hdl.handle.net/11452/22450
dc.identifier.volume20tr_TR
dc.identifier.wos000074977000005tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevier Irelanden_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalLung Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectRespiratory systemen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectConcomitant boosten_US
dc.subjectCisplatinumen_US
dc.subjectRadiosensitizeren_US
dc.subjectTherapy-oncology-groupen_US
dc.subjectHigh-dose radiationen_US
dc.subjectRandomized trialen_US
dc.subjectAdvanced headen_US
dc.subjectFractionation schemesen_US
dc.subjectTumor-controlen_US
dc.subjectNeck-canceren_US
dc.subjectCarcinomaen_US
dc.subjectSurvivalen_US
dc.subjectI/IIen_US
dc.subject.emtreeCisplatinen_US
dc.subject.emtreeRadiosensitizing agenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLung non small cell canceren_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreePhase 2 clinical trialen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRadiation doseen_US
dc.subject.emtreeSurvivalen_US
dc.subject.emtreeVomitingen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic agentsen_US
dc.subject.meshCarcinoma, non-small-cell lungen_US
dc.subject.meshCisplatinen_US
dc.subject.meshCombined modality therapyen_US
dc.subject.meshConfidence intervalsen_US
dc.subject.meshDose fractionationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLung neoplasmsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshProspective studiesen_US
dc.subject.meshRadiation-sensitizing agentsen_US
dc.subject.meshRadiotherapyen_US
dc.subject.meshSurvival analysisen_US
dc.subject.scopusChemoradiotherapy; Consolidation Chemotherapy; Intensity Modulated Radiation Therapyen_US
dc.subject.wosOncologyen_US
dc.subject.wosRespiratory systemen_US
dc.titleA phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung canceren_US
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus